Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido and ELYXYB for Commercially Insured Patients and the Addition of ELYXYB to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool
Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido and ELYXYB for Commercially Insured Patients and the Addition of ELYXYB to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool
Launching Co-Pay programs for ZTlido and ELYXYB for commercially insured patients
Multi-State Medicaid Pharmaceutical Purchasing Group added ELYXYB to its purchasing pool
为商业保险患者推出ztLido和ELYXYB的自付计划
多州医疗补助药品采购集团将ELYXYB添加到其采购池中
PALO ALTO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced launching of co-pay programs for both ZTlido and ELYXYB with the out-of-pocket costs for its product portfolio for commercially insured patients capped at $25 monthly, with certain eligible patients paying as low as $0. This applies to the Company's postherpetic neuralgia pain product, ZTlido, and migraine product, ELYXYB. Scilex has made significant investments to improve patient affordability and access to its products and continues to build on the Company's commitment to provide non-opioid pain management products to patients.
加利福尼亚州帕洛阿尔托，2024年4月9日（GLOBE NEWSWIRE）——专注于收购、开发和商业化用于治疗急慢性疼痛的非阿片类疼痛管理产品的创新创收公司Scilex控股公司（纳斯达克股票代码：SCLX，“Scilex” 或 “公司”）今天宣布自付启动ZTLido和ELYXYB的自付计划其针对商业保险患者的产品组合的费用上限为每月25美元，某些符合条件的患者支付的费用低至0美元。这适用于该公司的带状疱疹后遗神经痛止痛产品ztLido和偏头痛产品ELYXYB。Scilex已进行了大量投资，以提高患者的可负担性和获得其产品的机会，并将继续在公司向患者提供非阿片类药物疼痛管理产品的承诺基础上再接再厉。
Additionally, on April 1, 2024, a multi-state Medicaid pharmaceutical purchasing group added ELYXYB to its purchasing pool to make it eligible for thirteen States' Medicaid programs.
此外，2024年4月1日，一个多州医疗补助药品采购集团将ELYXYB添加到其购买池中，使其有资格参加13个州的医疗补助计划。
Scilex believes that high deductibles and co-pay programs should not prevent patients from receiving the medications they need. Scilex co-pay programs are designed to help patients reduce their co-pay and out-of-pocket costs for their medications. Our program partners with various assistance programs to help make patient medications more affordable.
Scilex认为，高免赔额和自付额计划不应阻止患者获得所需的药物。Scilex自付计划旨在帮助患者减少药物的自付费用和自付费用。我们的计划与各种援助计划合作，以帮助患者更实惠地使用药物。